Compare AES Corp (AES) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs IDEXX Laboratories, Inc. — how do they compare? AES Corp trades at $14.72 (market cap $10.49B), while IDEXX Laboratories, Inc. trades at $571.39 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.4× AES Corp's market cap, and AES Corp pays a 4.79% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| AES | IDXX | |
|---|---|---|
Market Cap | $10.49B | $46.22B |
Sector | Utilities | Health |
52-Week High | $17.28 | $766.68 |
52-Week Low | $12.51 | $526.44 |
Enterprise Value | $40.75B | $47.12B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.73, down slightly by 0.03%, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and 45.05% ROE, supported by recent earnings beats. A pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, dominates recent news, alongside a quarterly dividend of $0.18 per share.
The outlook is heavily influenced by the acquisition, offering a near-term upside to the $15 buyout price, but regulatory and shareholder approval risks remain. Long-term fundamentals are solid with projected revenue growth to $13.1 billion in 2026, though high debt levels and integration challenges post-acquisition pose risks. Analyst sentiment is mixed with a buy consensus of 43%.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
